Latest News for: copd

Edit

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Pharmiweb 15 Apr 2025
potential for broader use in chronic obstructive pulmonary disease (COPD) ... A phase 2/3 study in COPD is anticipated to begin in 2025 ... expanding clinical studies beyond COPD into chronic rhinosinusitis.
Edit

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD (Sanofi SA)

Public Technologies 15 Apr 2025
potential for broader use in chronic obstructive pulmonary disease (COPD) ... A phase 2/3 study in COPD is anticipated to begin in 2025 ... expanding clinical studies beyond COPD into chronic rhinosinusitis.
Edit

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD (Form 6-K) (Sanofi SA)

Public Technologies 02 Apr 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD ... Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the EU. About COPD.
Edit

Singing May Help COPD, Parkinson’s Disease, and Mood

The Epoch Times 31 Mar 2025
Sometimes help for wellness issues may come from an unexpected source ... Singing may also foster psychological health, as some studies indicate it boosts mood ... ....
Edit

Press Release: Dupixent Approved As The First-Ever Biologic Medicine In Japan For Patients With COPD

MENA FN 28 Mar 2025
(MENAFN - GlobeNewsWire - Nasdaq) Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was ... .
Edit

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Pharmiweb 28 Mar 2025
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, and chronic spontaneous urticaria (CSU) ... About COPD.
Edit

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD (Sanofi SA)

Public Technologies 28 Mar 2025
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, and chronic spontaneous urticaria (CSU) ... About COPD.
  • 1
×